Early Product Development, Pharmaceutical Sciences, IMED Biotech Unit , AstraZeneca Gothenburg , SE-431 83 , Mölndal , Sweden.
Institut des Sciences Analytiques (CNRS/ENS de Lyon/UCB Lyon 1), Centre de RMN à Très Hauts Champs , Université de Lyon , 69100 Villeurbanne , France.
Mol Pharm. 2018 Apr 2;15(4):1476-1487. doi: 10.1021/acs.molpharmaceut.7b01047. Epub 2018 Mar 12.
By the combined use of powder and single-crystal X-ray diffraction, solid-state NMR, and molecular modeling, the crystal structures of two systems containing the unusually large tenapanor drug molecule have been determined: the free form, ANHY, and a dihydrochloride salt form, 2HCl. Dynamic nuclear polarization (DNP) assisted solid-state NMR (SSNMR) crystallography investigations were found essential for the final assignment and were used to validate the crystal structure of ANHY. From a structural informatics analysis of ANHY and 2HCl, conformational ring differences in one part of the molecule were observed which influence the relative orientation of a methyl group on a ring nitrogen and thereby impact the crystallizability of the dihydrochloride salt. From quantum chemistry calculations, the dynamics between different ring conformations in tenapanor is predicted to be fast. Addition of HCl to tenapanor results in general in a mixture of protonated ring conformers and hence a statistical mix of diastereoisomers which builds up the amorphous form, a-2HCl. This was qualitatively verified by C CP/MAS NMR investigations of the amorphous form. Thus, to form any significant amount of the crystalline material 2HCl, which originates from the minor (i.e., energetically less stable) ring conformations, one needs to involve nitrogen deprotonation to allow exchange between the minor and major conformations of ANHY in solution. Thus, by controlling the solution pH value to well below the p K of ANHY, the equilibrium between ANHY and 2HCl can be controlled and by this mechanism the crystallization of 2HCl can be avoided and the amorphous form of the dichloride salt can therefore be stabilized.
通过粉末和单晶 X 射线衍射、固态 NMR 和分子建模的联合使用,已经确定了两个含有异常大的特南普诺药物分子的系统的晶体结构:游离形式 ANHY 和二盐酸盐形式 2HCl。动态核极化(DNP)辅助固态 NMR(SSNMR)晶体学研究被发现对于最终的结构确定至关重要,并用于验证 ANHY 的晶体结构。从 ANHY 和 2HCl 的结构信息学分析中,观察到分子中一个部分的构象环差异,这影响了一个环氮上甲基的相对取向,从而影响二盐酸盐的结晶能力。从量子化学计算预测,特南普诺中不同环构象之间的动态过程预计很快。盐酸的加入通常导致质子化环构象的混合物,从而形成无定形形式 a-2HCl 的非对映异构体的统计混合物。这通过对无定形形式的 C CP/MAS NMR 研究进行了定性验证。因此,为了形成任何大量的结晶物质 2HCl,它源于次要(即能量上不太稳定)的环构象,需要涉及氮去质子化,以允许 ANHY 在溶液中次要和主要构象之间的交换。因此,通过将溶液 pH 值控制在远低于 ANHY 的 p K 值以下,可以控制 ANHY 和 2HCl 之间的平衡,并通过这种机制避免 2HCl 的结晶,从而稳定二盐酸盐的无定形形式。